Detalles de la búsqueda
1.
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia.
Br J Clin Pharmacol
; 88(8): 3872-3882, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35277995
2.
In Vitro Metabolism of Slowly Cleared G Protein-Coupled Receptor 139 Agonist TAK-041 Using Rat, Dog, Monkey, and Human Hepatocyte Models (HepatoPac): Correlation with In Vivo Metabolism.
Drug Metab Dispos
; 49(2): 121-132, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33273044
3.
Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.
Epilepsia
; 61(7): 1491-1502, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32645213
4.
Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures.
Epilepsia
; 61(1): 125-137, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31912493
5.
Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Epilepsia
; 59(4): 866-876, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29574701
6.
Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
Epilepsy Behav
; 83: 50-58, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29653338
7.
Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies.
Epilepsia
; 58(1): 51-59, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27869305
8.
Perampanel with concomitant levetiracetam and topiramate: Post hoc analysis of adverse events related to hostility and aggression.
Epilepsy Behav
; 75: 79-85, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28830031
9.
Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial.
Epilepsia
; 57(2): 243-51, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26724782
10.
Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.
Epilepsia
; 57(7): 1120-9, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27221398
11.
Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials.
Br J Clin Pharmacol
; 82(2): 422-30, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27038098
12.
Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures.
Epilepsia
; 56(7): e90-4, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26096637
13.
Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel.
Epilepsia
; 56(8): 1252-63, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26140524
14.
Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies.
Epilepsy Behav
; 48: 45-52, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26057204
15.
Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies.
Epilepsia
; 55(3): 423-31, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24605793
16.
The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies.
Epilepsy Behav
; 35: 6-12, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24785428
17.
Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
Epilepsia
; 54(1): 117-25, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22905857
18.
Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Epilepsia
; 54(1): 126-34, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22905878
19.
Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Epilepsia
; 54(8): 1481-9, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23663001
20.
A multivariable prediction model of a major treatment response for focal-onset seizures: A post-hoc analysis of Phase III trials of perampanel.
Epilepsy Res
; 174: 106649, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34022524